ArticleInternational journal of environmental research and public health2020

Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.

Savvas S Ioannou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.